Search

Our goal of transforming the treatment of neuroendocrine carcinomas

Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).

Winners of 2020 BVDzero Case Awards

Winners of 2020 BVDzero Case Awards announced. 10 top clinical cases will receive a total prize of 15,000 euros.

Over 100 billion birds vaccinated with VAXXITEK

Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.

France

TwistPak Mixing platform for swine vaccines

TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds

H5N1: Bird flu again. What’s different now?

H5N1: how is avian influenza now? The virus known for affecting wild & domestic birds has been detected in dairy cows in the US. What you need to know.

2020 European PRRS Research Award sponsorship

2020 European PRRS Research Award: Boehringer Ingelheim calls for submissions

European_Commission_approves_nintedanibSSc-ILD

Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease

Boehringer Olaf Scholz break ground for innovation center

Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center

BI_X_Shanghai

Boehringer Ingelheim opens a second branch of its digital lab in Shanghai

Boehringer Ingelheim Social Engagements

Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions

Reduction of Salmonella in swine after vaccination

Authorities acknowledge reduction of Salmonella after vaccination with Enterisol® Ileitis

Transboundary animal diseases (TADs)

Avian influenza? Bluetongue virus? FMD? Learn what are transboundary animal diseases and how they can impact us

Transboundary animal diseases and veterinary preparedness

What are transboundary animal diseases (TADs)? Bluetongue virus, foot-and-mouth disease and avian influenza are pathogens belonging to this group.

European Metacam® indication expanded to guinea pigs

Boehringer Ingelheim adds a new species to its Metacam® brand in Europe, expanding the indications of this widely-used medicine to guinea pigs.

Classical Swine Fever live vaccine approved in China

Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved

DiaTEC new purification technology Ingelvac CircoFLEX

Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®

European Commission decision for Pradaxa® in children with VTE

Pradaxa® (dabigatran etexilate) receives EU marketing authorization for the treatment and prevention of VTE in children from birth to less than 18 years of age

reduced-heart-failure-treatment-approval-europe

European approval for treatment of adults with heart failure with reduced ejection fraction

Boehringer Ingelheim Venture Fund invests precision antimicrobials

Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials

world rabies day 2019

Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU

Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU

preserved-heart-failure-treatment-approval-europe

2020-Positive-business-momentum-despite-COVID-19-impact

While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.

BIVF funding more than doubled to 250 M€

Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers